Norio Ohmagari

Norio Ohmagari

Auto-generated profile, based on publicly available information

Norio Ohmagari

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2020 in Viruses
Verified
Journal Article
Open access
PDF file
MYMizuki Yamamoto
Mizuki Yamamoto
MKMaki Kiso
Maki Kiso
YSYuko Sakai-Tagawa
Yuko Sakai-Tagawa
KIKiyoko Iwatsuki-Horimoto
Kiyoko Iwatsuki-Horimoto
MIMasaki Imai
Masaki Imai
JIJunichiro Inoue
Junichiro Inoue
Although infection by SARS-CoV-2, the causative agent of coronavirus pneumonia disease (COVID-19), is spreading rapidly worldwide, no drug has been shown to be sufficiently effective for treating COVID-19. We previously found that nafamostat mesylate, an existing drug used for disseminated intravascular coagulation (DIC), effectively blocked Middle East respiratory syndrome coronavirus (MERS-CoV) S protein-mediated cell fusion by targeting transmembrane serine protease 2 (TMPRSS2), and inhibited MERS-CoV infection of human lung epithelium-derived Calu-3 cells. Here we established a quantitative fusion assay dependent on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) S protein, angiotensin I converting enzyme 2 (ACE2) and TMPRSS2, and found that nafamostat mesylate potently inhibited the fusion while camostat mesylate was about 10-fold less active. Furthermore, nafamostat mesylate blocked SARS-CoV-2 infection of Calu-3 cells with an effective concentration (EC)50 around 10 nM, which is below its average blood concentration after intravenous administration through continuous infusion. On the other hand, a significantly higher dose (EC50 around 30 μM) was required for VeroE6/TMPRSS2 cells, where the TMPRSS2-independent but cathepsin-dependent endosomal infection pathway likely predominates. Together, our study shows that nafamostat mesylate potently inhibits SARS-CoV-2 S protein-mediated fusion in a cell fusion assay system and also inhibits SARS-CoV-2 infection in vitro in a cell-type-dependent manner. These findings, together with accumulated clinical data regarding nafamostat’s safety, make it a likely candidate drug to treat COVID-19.

10 December 2020 in Viruses
Verified
Journal Article
Open access
PDF file
Seiya YamayoshiSeiya Yamayoshi
Seiya Yamayoshi
YSYUKO SAKAI-TAGAWA
YUKO SAKAI-TAGAWA
MKMichiko Koga
Michiko Koga
OAOsamu Akasaka
Osamu Akasaka
INIchiro Nakachi
Ichiro Nakachi
YKYoshihiro Kawaoka
Yoshihiro Kawaoka
Reverse transcription-quantitative PCR (RT-qPCR)-based tests are widely used to diagnose coronavirus disease 2019 (COVID-19). As a result that these tests cannot be done in local clinics where RT-qPCR testing capability is lacking, rapid antigen tests (RATs) for COVID-19 based on lateral flow immunoassays are used for rapid diagnosis. However, their sensitivity compared with each other and with RT-qPCR and infectious virus isolation has not been examined. Here, we compared the sensitivity among four RATs by using severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) isolates and several types of COVID-19 patient specimens and compared their sensitivity with that of RT-qPCR and infectious virus isolation. Although the RATs read the samples containing large amounts of virus as positive, even the most sensitive RAT read the samples containing small amounts of virus as negative. Moreover, all RATs tested failed to detect viral antigens in several specimens from which the virus was isolated. The current RATs will likely miss some COVID-19 patients who are shedding infectious SARS-CoV-2.

7 December 2022 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
HMHiroshi Mukae
Hiroshi Mukae
HYHiroshi Yotsuyanagi
Hiroshi Yotsuyanagi
NONorio Ohmagari
Norio Ohmagari
YDYohei Doi
Yohei Doi
HSHiroki Sakaguchi
Hiroki Sakaguchi
TUTakeki Uehara
Takeki Uehara
This phase 2b part of a randomized phase 2/3 study assessed the efficacy and safety of ensitrelvir for mild-to-moderate coronavirus disease 2019 (COVID-19) during the Omicron epidemic. Patients were randomized (1:1:1) to orally receive ensitrelvir fumaric acid 125 mg (375 mg on day 1) or 250 mg (750 mg on day 1) or placebo once daily for 5 days. The co-primary endpoints were the change from baseline in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) titer on day 4 and time-weighted average change from baseline up to 120 hours in the total score of predefined 12 COVID-19 symptoms. Safety was assessed through adverse events. A total of 341 patients (ensitrelvir 125-mg group: 114; ensitrelvir 250-mg group: 116; and placebo group: 111; male: 53.5–64.9%; mean age: 35.3–37.3 years) were included in the efficacy analyses. The change from baseline in SARS-CoV-2 titer on day 4 was significantly greater with both ensitrelvir doses than with placebo (differences from placebo: −0.41 log10 50% tissue-culture infectious dose/mL; P < .0001 for both). The total score of the 12 COVID-19 symptoms did not show a significant difference between the ensitrelvir groups and placebo group. The time-weighted average change from baseline up to 120 hours was significantly greater with ensitrelvir versus placebo in several subtotal scores, including acute symptoms and respiratory symptoms. Most adverse events were mild in severity. Ensitrelvir treatment demonstrated a favorable antiviral efficacy and potential clinical benefit with an acceptable safety profile. Japan Registry of Clinical Trials: jRCT2031210350 (https://jrct.niph.go.jp/en-latest-detail/jRCT2031210350)

21 October 2020 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
YMYusuke Miyazato
Yusuke Miyazato
SMShinichiro Morioka
Shinichiro Morioka
STShinya Tsuzuki
Shinya Tsuzuki
MAMasako Akashi
Masako Akashi
YOYasuyo Osanai
Yasuyo Osanai
NONorio Ohmagari
Norio Ohmagari
Some patients who recover from coronavirus disease 2019 (COVID-19) have prolonged symptoms such as dyspnea, fatigue, cough, and dysosmia for longer than 120 days after symptom onset. In addition, some patients who recovered from COVID-19 reported hair loss a few months after the onset of the disease. Alopecia is a late-onset symptom of COVID-19. The cause of alopecia is unknown; however, androgenic alopecia and telogen effluvium are possible causes.

27 March 2021 in Transactions of the Royal Society of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
PDF file
JBJesus Rodríguez Baño
Jesus Rodríguez Baño
GRGian Maria Rossolini
Gian Maria Rossolini
CSConstance Schultsz
Constance Schultsz
ETEvelina Tacconelli
Evelina Tacconelli
SMSrinivas Murthy
Srinivas Murthy
LPLaura Plant
Laura Plant
Antibiotic use in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients during the COVID-19 pandemic has exceeded the incidence of bacterial coinfections and secondary infections, suggesting inappropriate and excessive prescribing. Even in settings with established antimicrobial stewardship (AMS) programmes, there were weaknesses exposed regarding appropriate antibiotic use in the context of the pandemic. Moreover, antimicrobial resistance (AMR) surveillance and AMS have been deprioritised with diversion of health system resources to the pandemic response. This experience highlights deficiencies in AMR containment and mitigation strategies that require urgent attention from clinical and scientific communities. These include the need to implement diagnostic stewardship to assess the global incidence of coinfections and secondary infections in COVID-19 patients, including those by multidrug-resistant pathogens, to identify patients most likely to benefit from antibiotic treatment and identify when antibiotics can be safely withheld, de-escalated or discontinued. Long-term global surveillance of clinical and societal antibiotic use and resistance trends is required to prepare for subsequent changes in AMR epidemiology, while ensuring uninterrupted supply chains and preventing drug shortages and stock outs. These interventions present implementation challenges in resource-constrained settings, making a case for implementation research on AMR. Knowledge and support for these practices will come from internationally coordinated, targeted research on AMR, supporting the preparation for future challenges from emerging AMR in the context of the current COVID-19 pandemic or future pandemics.

1 January 2021 in Gene
Verified
Journal Article
Closed access
MSMasaya Sugiyama
Masaya Sugiyama
NKNoriko Kinoshita
Noriko Kinoshita
SISatoshi Ide
Satoshi Ide
HNHidetoshi Nomoto
Hidetoshi Nomoto
TNTakato Nakamoto
Takato Nakamoto
MMMasashi Mizokami
Masashi Mizokami